TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Novartis Phase III trial for next-generation malaria treatment KLU156 (GanLum) meets primary endpoint, with potential to combat antimalarial resistance

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Novartis Media Relations
Novartis Phase III trial for next-generation malaria treatment KLU156 (GanLum) meets primary endpoint, with potential to combat antimalarial resistance

Novartis announced successful Phase III trial results for KLU156 (GanLum), a novel malaria treatment with potential to combat drug-resistant parasites, achieving a 97.4% PCR-corrected cure rate across 12 African countries.

Insights
NVS   positive

Successfully completed Phase III trial for innovative malaria treatment, demonstrating high efficacy and potential to address drug resistance